AlloVir Inc

NASDAQ:ALVR   3:59:51 PM EDT
24.66
+0.15 (+0.61%)
Products

FDA Grants Orphan Drug Designation (ODD) To AlloVir’s Posoleucel For The Treatment of Virus-Associated Hemorrhagic Cystitis

Published: 10/04/2021 12:05 GMT
AlloVir Inc (ALVR) - FDA Grants Orphan Drug Designation (odd) to Allovir’s Posoleucel, an Allogeneic, Off-the-shelf, Multi-virus Specific T-cell Therapy, for the Treatment of Virus-associated Hemorrhagic Cystitis.
Allovir Inc - Phase 3 Registrational Study of Posoleucel in Virus-associated Hemorrhagic Cystitis is Ongoing.